Previous Close | 1.3200 |
Open | 1.3100 |
Bid | 1.2900 x 200 |
Ask | 1.3100 x 200 |
Day's Range | 1.2950 - 1.3150 |
52 Week Range | 0.7800 - 2.4800 |
Volume | |
Avg. Volume | 4,835,837 |
Market Cap | 272.267M |
Beta (5Y Monthly) | 0.84 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
With the business potentially at an important milestone, we thought we'd take a closer look at Akebia Therapeutics...
Akebia (AKBA) gains during premarket hours on Mar 28 as its key product Vafseo (vadadustat) tablets receive FDA's approval for the treatment of anemia due to chronic kidney disease.
The FDA, which turned away Akebia's initial application last March 2022, has a target action of Wednesday on the company's resubmission, which included safety data from tens of thousands of patients in Japan, where vadadustat was approved in mid-2020. Akebia has said it is prepping for a U.S. commercial launch of vadadustat in the second half if it gets an FDA green light.